What is Retatrutide?

Retatrutide is an investigational medication belonging to a class of multi-receptor agonists targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. It is being studied for its potential in managing obesity, type 2 diabetes, and metabolic disorders. By simultaneously acting on these pathways, retatrutide aims to improve blood sugar regulation, promote weight loss, and enhance overall metabolic health.

Retatrutide is administered via subcutaneous injection, typically on a weekly basis, under clinical supervision during its investigational phase.

• Generic name: Retatrutide
• Brand name: None (investigational compound)
• Drug classes: GLP-1, GIP, and glucagon receptor agonists

Warnings

• Retatrutide is currently under investigation and has not been approved by regulatory agencies for medical use.
• Do not use retatrutide if you have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
• Inform your doctor if you have a history of pancreatitis, as similar medications may increase this risk.
• Use retatrutide only under professional supervision as part of clinical trials or experimental protocols.

Before Using This Product

• Discuss your medical history with your healthcare provider, especially if you have type 1 diabetes, severe gastrointestinal conditions, or gallbladder issues.
• Inform your healthcare provider about all medications you are taking, as retatrutide may interact with other antidiabetic drugs or weight-loss agents.
• Ensure you understand the investigational nature of this compound and its potential risks and benefits.

How Should I Take Retatrutide?

• Administration: Retatrutide is administered via subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites to minimize irritation.
• Dosage: Doses are typically adjusted incrementally to assess tolerability and efficacy, as directed by clinical trial protocols.
• Frequency: Retatrutide is commonly administered once weekly during studies.

What Happens If I Miss a Dose?

• If you miss a dose, contact your clinical trial coordinator or healthcare provider for instructions.
• Do not double doses to make up for a missed dose unless directed by a healthcare professional.

What Happens If I Overdose?

• Symptoms of overdose may include severe nausea, vomiting, or hypoglycemia (low blood sugar).
• Seek medical attention immediately if you suspect an overdose.

What to Avoid

• Avoid using other GLP-1 receptor agonists, GIP agonists, or weight-loss medications without consulting your healthcare provider.
• Avoid alcohol consumption, as it may exacerbate side effects like gastrointestinal discomfort or hypoglycemia.
• Avoid self-administration of retatrutide outside of approved clinical settings.

Retatrutide Side Effects

Common side effects observed during clinical trials may include:

• Nausea
• Diarrhea
• Decreased appetite
• Vomiting
• Abdominal pain

Seek immediate medical attention if you experience severe or unusual symptoms, such as:

• Severe abdominal pain (may indicate pancreatitis)
• Persistent vomiting or dehydration
• Signs of a serious allergic reaction, such as swelling of the face, lips, or tongue
• Chest pain or irregular heartbeats